The Medicines Company Announces Launch of Public Offering of Common Stock
June 24 2019 - 5:30PM
Business Wire
The Medicines Company (NASDAQ:MDCO) (the “Company”) today
announced the launch of a public offering of $150.0 million of
shares of its common stock. In addition, the underwriters will be
granted a 30-day option to purchase from the Company up to an
additional $22.5 million of shares of common stock. The Company
expects to use the net proceeds of the offering to fund its
development of inclisiran and for general corporate purposes.
Goldman Sachs & Co. LLC and J.P. Morgan are acting as the
joint book-running managers and underwriters for the offering. A
registration statement relating to these securities has been filed
with the U.S. Securities and Exchange Commission (the “SEC”) and
became effective on June 24, 2019. A copy of the preliminary
prospectus supplement relating to the offering may be obtained for
free by visiting EDGAR on the SEC website at www.sec.gov.
Alternatively, the Company, any underwriter, or any dealer
participating in the offering will arrange to send you the
preliminary prospectus supplement if you request it by contacting:
Goldman Sachs & Co. LLC, 200 West Street, New York, New York
10282 or J.P. Morgan Securities LLC, 383 Madison Avenue, New York,
New York 10179.
This press release does not constitute an offer to sell or a
solicitation of an offer to buy the securities described above, nor
shall there be any sale of such shares of common stock in any state
or jurisdiction in which such offer, solicitation, or sale would be
unlawful prior to registration or qualification under the
securities laws of any such state or jurisdiction.
About The Medicines Company
The Medicines Company is a biopharmaceutical company with a
singular, relentless focus on addressing the greatest global
healthcare challenge and burden today – cardiovascular disease. Our
purpose is to halt the deadly progression of atherosclerosis and
the cardiovascular risk created by high levels of LDL-C, or bad
cholesterol. The Company is headquartered in Parsippany, New
Jersey.
Forward-Looking Statements
Statements contained in this
press release that are not purely historical, including, but not
limited to, statements about the Company, the proposed offering
described herein and the use of proceeds therefrom, are
forward-looking statements for purposes of the safe harbor
provisions under The Private Securities Litigation Reform Act of
1995. Without limiting the foregoing, the words “believes,”
“anticipates,” “plans,” “expects,” “should,” and “potential,” and
similar expressions, are intended to identify forward-looking
statements. These forward-looking statements involve known and
unknown risks and uncertainties that may cause the Company’s actual
results, levels of activity, performance or achievements to be
materially different from those expressed or implied by these
forward-looking statements. Important factors that may cause or
contribute to such differences include the ability of the Company
to effectively develop inclisiran; whether inclisiran will advance
in the clinical trials process on a timely basis or at all, or
succeed in achieving its specified endpoints; whether the Company
will make regulatory submissions for inclisiran on a timely basis;
whether its regulatory submissions will receive approvals from
regulatory agencies on a timely basis or at all; the extent of the
commercial success of inclisiran, if approved; the strength,
durability and life of the Company’s patent protection for
inclisiran and whether the Company will be successful in extending
exclusivity; and such other factors as are set forth in the risk
factors detailed from time to time in the Company’s periodic
reports and registration statements filed with the SEC, including,
without limitation, the risk factors detailed in the Company's
Quarterly Report on Form 10-Q filed with the SEC on April 26, 2019
and the preliminary prospectus supplement filed with the SEC on
June 24, 2019. The Company specifically disclaims any obligation to
update these forward-looking statements.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190624005714/en/
Investor Relations Krishna Gorti, M.D. Vice President,
Investor Relations 973 290 6122 krishna.gorti@themedco.com
Media Inquiries Michael Blash Vice President,
Communications 973 290 6100 michael.blash@themedco.com
Medicines (NASDAQ:MDCO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Medicines (NASDAQ:MDCO)
Historical Stock Chart
From Apr 2023 to Apr 2024